Novocure announced that Chief Executive Officer (CEO), Asaf Danziger, will retire at year-end 2024 and Novocure?s Chief Financial Officer (CFO), Ashley Cordova, will succeed him as the company?s next CEO. Mr. Danziger, who has served as CEO since 2002, will serve as Senior Advisor into early 2026, and will continue to serve on Novocure?s Board of Directors. These changes will become effective on January 1, 2025.
Asaf Danziger has served as Novocure?s Chief Executive Officer since 2002 and has been a member of the Board of Directors since 2012. Mr. Danziger was Novocure?s fourth employee, leading the organization from its preclinical development stage through regulatory approvals and product commercialization, growing Novocure into an organization with over $500 million in annual global sales and more than 1,500 employees. Mr. Danziger holds a Bachelor of Science in material engineering from Ben-Gurion University of the Negev, Israel.
Ashley Cordova has served as Novocure?s Chief Financial Officer since September 2020. She is responsible for global oversight of Novocure?s revenue and financial operations, including reimbursement activities, financial reporting, financial planning and analysis, treasury, tax, and investor relations. Joining Novocure in 2014, Ms. Cordova is a leader who combines strategic vision with emphasis on consistent operational excellence.
Throughout her tenure, Ms. Cordova has been integral to building Novocure?s global organization and preparing the company for its next stage of growth. She is a visible and engaged enterprise leader, committed to Novocure?s patient-forward mission. Prior to joining Novocure, Ms. Cordova served in various financial roles at Zoetis Inc. from 2012 to 2014 and Pfizer Inc. from 2005 to 2012.
Ms. Cordova graduated with a bachelor?s degree in music and business from Furman University and earned her International Master of Business Administration from the University of South Carolina. Ms. Cordova currently serves on the Board of Directors of Therabody Inc.
